Expanding the possibilities of migraine attack relief: effcacy and safety of zolmitriptan and patient reports
https://doi.org/10.33667/2078-5631-2021-22-31-36
Abstract
A large number of patients are taking triptans due to ineffectiveness or contraindications to the use of non-steroidal anti-inflammatory drugs.
Aim. Study of the effcacy and safety of Zolmitriptan-SZ, as well as its comparative analysis with other drugs for the relief of migraine attacks based on patient self-reports.
Materials and methods. In an open, uncontrolled post-marketing observational study of the effcacy and safety of Zolmitripan-SZ for the relief of migraine attacks, 50 patients with migraine were included. All patients were given questionnaires to collect demographic and health information, as well as a diary for two migraine attacks.
Results. The average age of the participants was 40.3 ± 8.5 years (89.5 % were women, 10.5 % were men). After 1 hour, the pain stopped completely in 26.4 % of attacks, after 2 hours – in 78.0 %. Taking into account the return of headache in some patients, after 24 hours 65.9% patients were headache-free. There was also a signifcant reduction in the prevalence of nausea and photo-, phonophobia. Patients reported good effect in 59.6% of attacks and excellent effect in 24.7% of attacks.
Conclusion. Conclusion: Zolmitriptan SZ provides safe and effective migraine attack relief.
About the Authors
N. V. Latysheva
Alexander Vein Headache Clinic. I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Latysheva Nina V., DM Sci, associate professor at Dept of Nervous Diseases of Institute of Professional Education
Scopus: 24492160100
Moscow
E. G. Filatova
Alexander Vein Headache Clinic. I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Filatova ElenaG., DM Sci, professor at Dept of Nervous Diseases of Institute of Professional Education
Moscow
A. V. Berdnikova
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Berdnikova Anna V., clinical resident at Dept of Nervous Diseases, Faculty of Medicine
Moscow
References
1. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992; 267: 64–69.
2. Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, Harrison W; ID Migraine validation study. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003; 61 (3): 375–382.
3. Steiner TJ, Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, Katsarava Z, Queiroz LP, Scher AI, Tekle-Haimanot R, Wang SJ, Martelletti P, Dua T, Chatterji S. Improving quality in population surveys of headache prevalence, burden and cost: key methodological considerations. J Headache Pain. 2013; 14 (1): 87.
4. Buse DC, Fanning KM, Reed ML, et al. Life with migraine: effects on relationships, career, and fnances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 2019; 59: 1286–1299.
5. Steiner TJ, Stovner LJ, Vos T, et al. Migraine is frst cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018; 19 (1): 17.
6. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003; 290: 2443–2454.
7. Ashina M, Katsarava Z, Do TP, Buse DC, et al. Migraine: epidemiology and systems of care. Lancet. 2021; 397: 1485–1495.
8. Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954–976.
9. Ebell M. Diagnosis of migraine headache. Am Fam Physician. 2006; 74 (12): 2087–2088.
10. Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015; 84 (7): 688–695.
11. Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Saf. 2003; 26 (2): 93–107.
12. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache. 2003; 43: 36–44.
13. Headache Classifcation Committee of the International Headache Society. The International Classifcation of Headache Disorders. Cephalalgia. 2018; 38 (3rd edition): 1–211.
14. Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015 Jul–Aug;55 Suppl. 4: 221–35.
15. Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, Goadsby PJ. Comparative effcacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia. 2014 Apr; 34 (4): 258–67.
16. Xu H, Han W, Wang J, Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016 Dec; 17 (1): 113.
Review
For citations:
Latysheva N.V., Filatova E.G., Berdnikova A.V. Expanding the possibilities of migraine attack relief: effcacy and safety of zolmitriptan and patient reports. Medical alphabet. 2021;(22):31-36. (In Russ.) https://doi.org/10.33667/2078-5631-2021-22-31-36
Views:
365
Email this article 